期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 8, 期 8, 页码 1187-1199出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.8.1187
关键词
bradykinin; coagulation; complement cascade; contact cascade; DX-88; ecallantide; hereditary angioedema; kallikrein; peptide inhibitor
Background: Plasma kallikrein plays a major role in the contact (kallikrein-kinin) cascade producing bradykinin. Bradykinin is a vasodilator, which increases vascular permeability, activates inflammation and produces pain. Plasma kallikrein is also crosslinked to the coagulation system and the complement cascade. Objective: Ecallantide (DX-88) is a potent and specific inhibitor of plasma kallikrein. Ecallantide is a recombinantly produced and engineered small protein based on the first Kunitz domain of human tissue factor pathway inhibitor. It was identified through phage display technology. Methods: The search terms 'ecallantide', TX-88' and 'hereditary angioedema' were entered into Pubmed/Medline, ClinicalTrials and Google. Results/conclusion: At present, the drug is being studied for two major indications. First, the results for the treatment of hereditary angioedema are promising. Second, a prospective randomised multi-centre trial for the reduction of blood loss during on-pump cardiothoracic surgery will be terminated in October 2008.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据